Eagle Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Eagle Pharmaceuticals, Inc.
Eagle Pharmaceuticals has received approval for a new indication in Japan for its Treakisym (bendamustine) used to diffuse large B-cell lymphoma. The company is looking to expand as it expects the new indication to generate an opportunity worth up to $25m.
Eagle Pharmaceuticals was gearing up for patent-litigation proceedings with Endo over Vasostrict on 1 February but has quickly seen the landscape shift.
As Apotex names its new US president and CEO, Akorn puts together a fresh board of directors following bankruptcy proceedings. Stada has made new appointments in Germany, while Siegfried makes significant changes in its leadership roles.
Endo is leaving the door wide open to settle its patent-litigation showdown with Eagle Pharmaceuticals over Vasostrict (vasopressin), after Eagle said it was mulling an ‘at-risk’ launch.
- Generic Drugs
- Specialty Pharmaceuticals
- Large Molecule
- Other Names / Subsidiaries
- Arsia Therapeutics
- Eagle Biologics